Do not use the same spot every week
There is no evidence of direct interaction between these medications, and emergency contraception should be taken as soon as possible after unprotected intercourse for maximum effectiveness
those with less common alleles may require 68 weeks to notice meaningful appetite change
Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) is not approved for use during pregnancy, and animal studies suggest potential risks to fetal development
This large-scale analysis suggests that OSA status may act as an effect modifier in the association between GLP-1-RA prescription and mortality. The results of this study may lead to OSA diagnosis identifying diabetes patients more likely to derive mortality benefit from GLP-1 therapythe 20% greater relative mortality reduction in patients with OSA supports considering OSA status when making GLP-1 prescribing decisions, the investigators say
SURMOUNT-1 Trial (Tirzepatide for Weight Loss in Adults with Obesity): Duration: 72 weeks (18 months) Participants: Adults with BMI 30+ or 27+ with comorbidities Intervention: Weekly tirzepatide injections + lifestyle counseling Average weight loss results in clinical trials of FDA-approved tirzepatide: Dose-dependent response: Higher doses produced greater weight loss Average range across doses: 15-22% of body weight over 72 weeks For context: A 230-pound person losing 20% would lose approximately 46 pounds Placebo (lifestyle alone): Approximately 3% of body weight Key findings: Weight loss was gradual, not rapid (took a full 72 weeks to reach maximum) Higher doses produced more weight loss (dose-response relationship) Almost everyone lost some weight, but the amount varied dramatically Lifestyle counseling was included (not medication alone) Individual Variation: Why Results Differ The clinical trial averages mask huge individual variation
/assets/images/provider/photos/2775905.jpeg)
